12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Company News  |  Deals

Columbia Laboratories, Watson deal

Columbia transferred to partner Watson regulatory responsibility and an NDA in the U.S. for Prochieve vaginal progesterone gel to reduce the risk of pretern birth in women with short uterine cervical length in the mid-trimester of pregnancy.The transfer was part of the terms of the...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >